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Purpose: Clinical implications of single patient classifier (SPC) and microsatellite instability (MSI) in stage II/III gastric cancer 
have been reported. We investigated SPC and the status of MSI and Epstein-Barr virus (EBV) as combinatory biomarkers to pre-
dict the prognosis and responsiveness of adjuvant chemotherapy for stage II/III gastric cancer. 
Materials and Methods: Tumor specimens and clinical information were collected from patients enrolled in CLASSIC trial, a 
randomized controlled study of capecitabine plus oxaliplatin-based adjuvant chemotherapy. The results of nine-gene based SPC 
assay were classified as prognostication (SPC-prognosis) and prediction of chemotherapy benefit (SPC-prediction). Five quasi-
monomorphic mononucleotide markers were used to assess tumor MSI status. EBV-encoded small RNA in situ hybridization was 
performed to define EBV status.  
Results: There were positive associations among SPC, MSI, and EBV statuses among 586 patients. In multivariate analysis of dis-
ease-free survival, SPC-prognosis [hazard ratio (HR): 1.879 (1.101–3.205), 2.399 (1.415–4.067), p=0.003] and MSI status (HR: 0.363, 
95% confidence interval: 0.161–0.820, p=0.015) were independent prognostic factors along with age, Lauren classification, TNM 
stage, and chemotherapy. Patient survival of SPC-prognosis was well stratified regardless of EBV status and in microsatellite sta-
ble (MSS) group, but not in MSI-high group. Significant survival benefit from adjuvant chemotherapy was observed by SPC-Pre-
diction in MSS and EBV-negative gastric cancer. 
Conclusion: SPC, MSI, and EBV statuses could be used in combination to predict the prognosis and responsiveness of adjuvant 
chemotherapy for stage II/III gastric cancer.
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INTRODUCTION 
Surgery and chemotherapy are the main treatment strategies 
against most solid cancers. Recently developed technologies 
and updates in the understanding of cancer biology have 
made it possible to classify cancers according to their molecu-
lar characteristics. These achievements have opened the era 
of precision medicine against cancer,1-3 and various biomark-
ers and algorithms are being used in clinical practice to de-
cide treatment strategies, as they can predict the prognosis 
and responsiveness to chemotherapy in various cancers.4-6 
Gastric cancer is one of the most common and lethal malig-
nancies in the world, especially in Korea. Various efforts have 
been made to understand gastric cancer at molecular level, 
hoping that the findings may have clinical utility.7-9 For exam-
ple, through integrated analyses using multi-omics platforms, 
the Cancer Genome Atlas study has identified four molecular 
subtypes of gastric cancer, including Epstein-Barr virus (EBV), 
microsatellite instability (MSI), chromosomal instability 
(CIN), and genomic stable (GS) types, with distinctive biologi-
cal characteristics. Although a promising utility of MSI in 
making clinical decisions has been extensively reported,10-14 
concrete evidence is still needed to confirm clinical utility of 
other subtypes; currently, no assay is available for applying 
routine use to identify certain molecular subtypes such as CIN 
and GS, which prevents the accumulation of standardized ev-
idence. In this regard, we have developed a predictive test on 
GMP-grade qRT-PCR assay platform for predicting the prog-
nosis and response to adjuvant chemotherapy after D2 gas-
trectomy for stage II/III gastric cancer: single patient classifier 
(SPC).15,16 Based on gene expression profiling, SPC translates 
clinically relevant molecular characteristics in gastric cancer 
(i.e., immune, stem-like, and epithelial type characteristics) 
into SPC-prognosis (low, intermediate, and high-risk groups) 
and SPC-prediction subtypes (responder and non-responder 
groups for adjuvant chemotherapy), serving as an accessible 
tool for the molecular subtyping of gastric cancer, along with 
EBV or MSI.
Taken together, we believe that from a practical standpoint, 
it would be worthwhile to evaluate the combinatory effects of 
clinically relevant subtypes, such as SPC, MSI, and EBV, in or-
der to make a more precise stratification of patients for their 
prognosis and predict their responsiveness to adjuvant che-
motherapy.
MATERIALS AND METHODS
Study design and patients
From a total of 1035 patients enrolled in CLASSIC trial, which 
is a randomized controlled study of capecitabine plus oxalipl-
atin-based adjuvant chemotherapy for stage II/III gastric can-
cer,17,18 we reviewed the medical records of 586 patients, for 
whom it was possible to identify SPC, MSI and EBV statuses. 
Of these, 282 patients underwent D2 gastrectomy alone, while 
304 patients underwent D2 gastrectomy plus adjuvant che-
motherapy. This study was approved by the Institutional Re-
view Board at Severance Hospital, Yonsei University Health 
System (IRB No: 4-2016-0068, 4-2016-0433).
Definition of SPC status 
We had previously analyzed the expression of four classifier 
genes (GZMB and WARS representing immune module, 
SFRP4 representing stem-like module, and CDX1 represent-
ing intestinal epithelial module) and five reference genes 
(ACTB, ATP5E, HPRT1, GPX1, and UBB) by performing a real-
time RT-PCR assay (nProfiler 1 Stomach Cancer Assay, No-
vomics Co., Ltd., Seoul, Korea) using samples from CLASSIC 
trial cohort.15 Prognostication (SPC-prognosis; low-risk, inter-
mediate-risk or high-risk) and prediction of chemotherapy 
benefit (SPC-prediction; responder or non-responder) were 
defined according to the expression results of these nine 
genes from SPC assay. 
Definition of MSI status 
Previously, we had also analyzed MSI status from CLASSIC 
trial cohort using a panel (MSI Analysis System, Version 1.2; 
Promega, Madison, WI, USA) of five quasi-monomorphic 
mononucleotide repeat markers (NR-21, BAT-25, MONO-27, 
NR-24, and BAT-26) that determined MSI status of the tumor 
with high accuracy.13 MSI-H was defined as instability of two 
or more of the five markers, whereas MSI-L and microsatellite 
stable (MSS) were defined as instability of one marker and 
those without instability.19,20 
Epstein-Barr virus-encoded small RNA in situ 
hybridization
Two core tissue microarrays, with a diameter of 3 mm for each 
case, were constructed from formalin-fixed paraffin-embed-
ded tumor blocks. Ventana Benchmark ISH system (Ventana 
ISH iView kit, Ventana Corporation, Tucson, AZ, USA) was 
used for Epstein-Barr virus-encoded small RNA in situ hy-
bridization (EBER-ISH).21 The presence of EBV in tumor cells 
in EBER-ISH analysis was considered as a positive result; the 
absence of EBV was considered an EBV-negative result. 
Statistical analysis
Chi-square test or Fisher’s exact test were performed for cate-
gorical variables. Continuous variables were analyzed with 
independent t test. Disease-free survival (DFS) was defined as 
the time from surgery to recurrence or death, whichever oc-
curred first. Survival data were censored at the last time of fol-
low-up or at seven years for patients without these events. 
DFS curves were generated using Kaplan-Meier method and 
log-rank test. Cox proportional hazards regression models 
were used to obtain hazard ratios (HRs) with 95% confidence 
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interval (CI). The forward likelihood-ratio model was used for 
selecting inclusion variables in the final multivariable model, 
using an entry criterion between 0.15 and 0.25 as significance 
level. Two-sided p values less than 0.05 were considered sta-
tistically significant. Data were analyzed using IBM SPSS ver-
sion 23.0 (IBM Corp., Armonk, NY, USA).
RESULTS
Baseline characteristics of study cohort 
Table 1 shows clinical information of the study cohort (n=586) 
of the current study. Between the original CLASSIC cohort 
(n=1035) and this collected cohort, no significant differences 
were observed;13,15 70 (11.9%), 278 (47.4%), and 238 (40.6%) 
patients were classified into low-, intermediate-, and high-risk 
groups, respectively, by SPC-prognosis, and 318 (54.3%) and 
268 (45.7%) of patients were classified as non-responders and 
responders, respectively, by SPC-prediction. Furthermore, 39 
(6.7%) patients showed MSI-H tumors and 41 patients (7.0%) 
showed EBV-positive tumors. Detailed baseline and clinical 
demographics by SPC and MSI have been reported in previ-
ous studies.13,15 With regards to EBV status, no statistically sig-
nificant distribution was observed between EBV-positive and 
-negative cases for clinical variables such as age, Lauren clas-
sification, pathologic stages, and treatment, but not gender; 
most cases of EBV-positive gastric cancer were observed in 
men (38 out of 41 patients, 92.7%, p=0.001; chi-square test) 
(Table 2). 
Associations of MSI and EBV statuses with respect 
to SPCs
With regards to SPC-prognosis, both MSI and EBV statuses 
had a positive association (Table 3). MSI-H and EBV-positive 
tumors were dominant in low-risk group compared to that in 
other groups (p<0.001 for both statuses; chi-square test). With 
regards to SPC-prediction, 27 (69.2%) of 39 MSI-H patients 
and 38 (92.7%) of 41 EBV-positive patients were enriched in 
non-responder group (p=0.066 and <0.001, respectively). 
Aside from SPC, MSI and EBV statuses were almost mutually 
exclusive; only two patients had both MSI-H and EBV-positive 
gastric cancer (p>0.999). 
Table 1. Clinical Characteristics of Entire Cohort
Entire cohort (n=586)
Age (yr) 56.1±11.6
Sex
Male 410 (70.0)
Female 176 (30.0)
Lauren classification 
Intestinal 215 (36.7)
Non-intestinal 371 (63.3)
EBV status
Negative 541 (93.0)
Positive 41 (7.0)
MSI status
MSS/MSI-L 547 (93.3)
MSI-H 39 (6.7)
Treatment
Surgery only 282 (48.1)
Surgery+CTx 304 (51.9)
pTNM stage*
II 276 (47.1)
III 310 (52.9)
SPC-prognosis
Low-risk 70 (11.9)
Intermediate-risk 278 (47.4)
High-risk 238 (40.6)
SPC-prediction
Non-responder 318 (54.3)
Responder 268 (45.7)
EBV, Epstein-Barr virus; MSI, microsatellite instability; MSS, microsatellite 
stable; MSI-L, microsatellite instability-low; MSI-H, microsatellite instability-
high; CTx, adjuvant chemotherapy (capecitabine plus oxaliplatin); SPC, single 
patient classifier.
Data are expressed as mean±standard deviation or as n (%).
*According to American Joint Committee on Cancer 6th edition.
Table 2. Clinical Characteristics of Patients according to EBV Status
EBV status
Negative 
(n=541)
Positive 
(n=41)
p value
Age (yr) 56.2±11.6 55.9±11.5 0.885
Sex 0.001
Male 371 (68.6) 38 (92.7)
Female 170 (31.4) 3 (7.3)
Lauren classification 0.486
Intestinal 201 (37.2) 13 (31.7)
Non-intestinal 340 (62.8) 28 (68.3)
pTNM stage* 0.274
II 259 (47.9) 16 (39.0)
III 282 (52.1) 25 (61.0)
pT classification* 0.408
pT1/T2 300 (55.5) 20 (48.8)
pT3/T4 241 (44.5) 21 (51.2)
pN classification* 0.379
pN0 48 (8.9) 2 (4.9)
pN1/N2/N3 493 (91.1) 39 (95.1)
Treatment 0.663
Surgery only 258 (47.7) 21 (51.2)
Surgery+CTx 283 (52.3) 20 (48.8)
EBV, Epstein-Barr Virus; CTx, adjuvant chemotherapy (capecitabine plus ox-
aliplatin).
Data are expressed as mean±standard deviation or as n (%), unless other-
wise specified.
*According to American Joint Committee on Cancer 6th edition.
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 Prognosis according to markers
In the study cohort, both SPC and MSI statuses were prognos-
tic factors, but EBV was not (p=0.001 in SPC-prognosis, 
p=0.003 in MSI-H vs. MSS/MSI-L, p=0.547 in EBV positive vs. 
EBV negative; log-rank test). 
We first examined the combinatory effects of SPC and MSI 
statuses in prognostication. In Fig. 1A, different prognoses of 
low-, intermediate-, and high-risk groups obtained from SPC-
prognosis were well-preserved in MSS/MSI-L patients [HR: 
1.787 (1.000–3.191) in intermediate-risk, 2.510 (1.411–4.463) 
in high-risk group, log-rank p=0.001], but not in MSI-H pa-
tients (log-rank p=0.316), indicating that SPC and MSI status-
es were independent of one another in prognostication. A 
multivariate analysis using Cox proportional hazards regres-
Table 3. Associations between SPC, MSI, and EBV Status
SPC-prognosis SPC-prediction EBV
Low-risk Intermediate-risk High-risk p value Non-responder Responder p value Negative Positive p value
MSI status <0.001 0.066 >0.999
MSS/MSI-L 57 (81.4) 261 (93.9) 229 (96.2) 291 (91.5) 256 (95.5) 504 (93.2) 39 (95.1)
MSI-H 13 (18.6) 17 (6.1) 9 (3.8) 27 (8.5) 12 (4.5) 37 (6.8) 2 (4.9)
EBV <0.001 <0.001
Negative 47 (68.1) 262 (94.6) 232 (98.3) 276 (87.9) 265 (98.9)
Positive 22 (31.9) 15 (5.4) 4 (1.7) 38 (12.1) 3 (7.3)
SPC, single patient classifier; MSI, microsatellite instability; EBV, Epstein-Barr virus; MSS, microsatellite stable; MSI-L, microsatellite instability-low; MSI-H, mi-
crosatellite instability-high.
Data are expressed as n (%). 
Fig. 1. Kaplan-Meier and log-rank comparisons of DFS in patients with 
stage II/III gastric cancer according to (A) status of MSI and SPC-prog-
nosis, (B) status of EBV and SPC-prognosis, (C) EBV status and treatment. 
DFS, disease-free survival; MSI, microsatellite instability; SPC, single pa-
tient classifier; MSS, microsatellite stable; MSI-L, microsatellite instabili-
ty-low; MSI-H, microsatellite instability-high; EBV, Epstein-Barr virus; CTx, 
adjuvant chemotherapy (capecitabine plus oxaliplatin).
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sion models showed that both MSI status (HR: 0.363, 95% CI: 
0.161–0.820, p=0.015) and SPC-prognosis [HR: 1.879 (1.101–
3.205) in intermediate-risk, 2.399 (1.415–4.067) in high-risk 
group, p=0.003] were independently significant prognostic 
factors for DFS, in addition to age, chemotherapy, pTNM 
stage, and Lauren classification (Table 4). 
In contrast, a combination of SPC and EBV statuses re-
vealed a distinct trend whereby the survival by SPC-prognosis 
was well-stratified regardless of EBV status (Fig. 1B). Intrigu-
ingly, in EBV-positive patients, the difference in DFS between 
SPC-prognosis groups was highly significant [HR: 2.608 
(0.735–9.254) in intermediate-risk, 17.656 (3.839–81.200) in 
high-risk group, log-rank p<0.001], necessitating further in-
vestigation. In a multivariate analysis, EBV status was not 
found to be a significant prognostic factor for DFS [HR: 0.735 
(0.425–1.268), p=0.268], in addition to age, sex, chemotherapy, 
and pTNM stage.
 
Responsiveness to adjuvant chemotherapy according 
to markers
Statistically significant survival benefit from adjuvant chemo-
therapy was observed in responder group for SPC-prediction, 
MSS/MSI-L groups, and EBV-negative groups (p=0.001, 0.002, 
and 0.001, respectively; log-rank test), but not in non-respond-
er group for SPC-prediction, MSI-H groups, and EBV-positive 
groups (p=0.243, 0.931, and 0.687, respectively) (Fig. 1C). 
To explore the survival benefit from adjuvant chemothera-
py by joint markers, we categorized patients into the follow-
ing: 1) responder/MSI-H, non-responder/MSI-H, responder/
MSS/MSI-L, and non-responder/MSS/MSI-L for joint analy-
sis of SPC and MSI and 2) responder/EBV-positive, non-re-
sponder/EBV-positive, responder/EBV-negative, and non-re-
sponder/EBV-negative for joint analysis of SPC and EBV.
In both non-responder/MSI-H and responder/MSI-H pop-
ulations, no prognostic difference was observed between sur-
gery alone and surgery plus chemotherapy (p=0.630 and 
0.317, respectively). In contrast, in MSS/MSI-L patients, a sig-
nificant survival benefit from adjuvant chemotherapy was 
seen in responder group of SPC-prediction (p=0.001) (Fig. 
2A), but not in non-responder group (p=0.168) (Fig. 2B).  
In case of joint SPC/EBV, for responder/EBV-positive pa-
tients, survival benefit from adjuvant chemotherapy was not 
analyzed since all of the three patients underwent surgery 
alone. In the remaining population, the trend of survival ben-
efit in joint SPC/EBV was similar to that for joint SPC/MSI. In 
non-responder/EBV-positive patients, no survival benefit 
from adjuvant chemotherapy was observed (p=0.491; n=18 
and 20 for surgery alone and adjuvant chemotherapy group, 
respectively). For EBV-negative patients, responder group of 
SPC-prediction gained a significant survival benefit from ad-
juvant chemotherapy (p=0.006) (Fig. 2C), whereas non-re-
sponder group did not (p=0.587) (Fig. 2D). 
DISCUSSION
We examined the combinatory effect of clinically relevant 
subtypes, SPC, MSI, and EBV, in the prediction of prognosis 
and chemotherapy response after surgery using a cohort of 
586 patients enrolled in CLASSIC trial, a randomized con-
trolled study of capecitabine plus oxaliplatin-based adjuvant 
chemotherapy for stage II/III gastric cancer. The three mark-
ers used in this study, SPC, MSI, and EBV, were based on dif-
ferent biological, pathological, or etiological grounds. SPC 
classified patients by immune, stem-like, and epithelial char-
acteristics from the gene expression profile of tumor tissues, 
while MSI-H and EBV-positive tumors were associated with 
genetic hypermutability due to impaired DNA mismatch re-
pair and exogeneous viral infection, respectively. Thus, we ex-
pected that our joint marker analysis would discover new 
findings clinically meaningful to patient selection. It was also 
considered that the use of these markers or some of their 
combinations would be comparatively feasible to be intro-
duced into practice.
In the analyses evaluating the combinatory prognostic ef-
fects of SPC, MSI, and EBV, joint SPC/MSI and SPC/EBV 
showed their respective clinical implications. 1) SPC and MSI 
were independent prognostic factors. Although i) MSI-H tu-
mors have been known for their activated immune response 
and ii) SPC and MSI have a positive association, the propor-
tion of MSI-H was slightly higher in low-risk group than in 
Table 4. Disease-Free Survival Analyzed by a Multivariate Cox Propor-
tional-Hazards Model
HR (95% CI) p value
Age 1.015 (1.003–1.027) 0.013
Treatment <0.001
Surgery only Reference
Surgery+CTx 0.621 (0.475–0.811)
pTNM stage* <0.001
II Reference
III 2.160 (1.621–2.879)
Lauren classification 0.024
Intestinal Reference
Non-intestinal 1.421 (1.048–1.927)
MSI status 0.015
MSS/MSI-L Reference
MSI-H 0.363 (0.161–0.820)
SPC prognosis 0.003
Low-risk Reference
Intermediate-risk 1.879 (1.101–3.205) 0.021
High-risk 2.399 (1.415–4.067) 0.001
HR, hazard ratio; CI, confidence interval; CTx, adjuvant chemotherapy 
(capecitabine plus oxaliplatin); SPC, single patient classifier; MSI, microsat-
ellite instability; MSS, microsatellite stable; MSI-L, microsatellite instability-
low; MSI-H, microsatellite instability-high.
*According to American Joint Committee on Cancer 6th edition.
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other groups (p<0.001; chi square test) and low-risk/MSS/
MSI-L patients had as good a prognosis as MSI-H patients 
(p=0.001; log-rank test), indicating that aside from MSI status, 
SPC identifies patients whose long-term survival is anticipat-
ed. 2) EBV was not a significant prognostic factor in this co-
hort. SPC/EBV, however, showed the most dramatic stratifica-
tion between low-risk and high-risk patients in EBV-positive 
group. As low-risk and high-risk groups in SPC scheme were 
associated with immune and stem-like characteristics, re-
spectively, the result implies that not all EBV-positive patients 
might have the same immune response, supporting the exis-
tence of molecular heterogeneity in EBV-associated gastric 
cancers.21,22 
SPC, MSI, and EBV statuses identified two groups of pa-
tients in the present CLASSIC cohort: those who gained sur-
vival benefit from adjuvant chemotherapy and those who did 
not. The combination of SPC/MSI or SPC/EBV led to a more 
elaborate selection of these patient groups. 1) It has generally 
been accepted that MSI-H patients do not benefit from che-
motherapy, whereas MSS/MSI-L patients do.5,12,13 The combi-
natory SPC and MSI statuses further classified patients in 
MSS/MSI-L population who did not benefit from chemother-
apy. 2) SPC/EBV worked in a manner similar to that of SPC/
MSI. EBV-positive patients did not gain chemotherapy bene-
fits, while EBV-negative patients did. Joint SPC/EBV further 
selected patients from EBV-negative population who did not 
gain chemotherapy benefits. The combinatory use of SPC, 
MSI, and EBV might guide clinical decisions with regards to 
chemotherapeutic treatment. 
Currently, accumulating studies have reported that patients 
Fig. 2. Kaplan-Meier and log-rank comparisons of DFS in patients with stage II/III gastric cancer following treatment in subgroups of (A) MSS/MSI-L and 
SPC responder group, (B) MSS/MSI-L and SPC non-responder group, (C) EBV-negative and SPC responder group, and (D) EBV-negative and SPC non-
responder group. DFS, disease-free survival; CTx, adjuvant chemotherapy (capecitabine plus oxaliplatin); MSS, microsatellite stable; MSI-L, microsatellite 
instability-low; SPC, single patient classifier; EBV, Epstein-Barr virus.
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with MSI-H and EBV-positive gastric cancer dramatically re-
sponded to immune checkpoint inhibitors.23 As defined by 
the immune-related characteristics, low-risk/non-responder 
SPC subtype could be another companion diagnostic candi-
date for immune therapy. Otherwise, the combinatory use of 
SPC, MSI, and EBV may yield meaningful knowledge on the 
immunological landscape of gastric cancer, leading to a better 
selection of patients for immune therapy and improvement in 
response rates. 
This study had some limitations. First, although the distri-
bution of clinical variables of the study cohort (n=586) was 
similar to that of the original CLASSIC trial cohort (n=1035), 
the possibility of selection bias cannot be overlooked. Second, 
due to a limited number of cases and events, type II error 
needs to be considered, especially in subgroup analysis. Al-
though the present results were from a randomized controlled 
trial (RCT), additional validation with qualified specimens 
should be conducted to reach a substantial consensus of the 
clinical role of these markers in patients with gastric cancer. 
Using specimens from other RCTs, such as MAGIC,12,24 ART-
IST,25 or FLOT26 trials, would be the most reliable and practical 
option. 
In conclusion, SPC, MSI, and EBV positivity could be used 
in a combinatory manner to predict the prognosis and respon-
siveness of adjuvant chemotherapy for stage II/III gastric cancer. 
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